2016
DOI: 10.17116/jnevro201611612249-54
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacotherapy of anxiety disorders in patients with chronic cerebral ischemia

Abstract: новная причина микроангиопатии -артериальная гипертензия (АГ). Церебральная микроангиопатия приводит к мультифокальному поражению мозга и клинически манифестирует комбинацией аффек-тивных, когнитивных (преимущественно лобных) и двигательных нарушений. Наиболее ранними кли-ническими маркерами недостаточности церебраль-ной перфузии являются расстройства тревожно-де-прессивного спектра, проявляющиеся множеством неспецифических жалоб преимущественно астени-ческого характера, за которыми скрываются мягкие когнитивн… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 8 publications
0
1
0
Order By: Relevance
“…However, adjustments of doses were complex and needed further investigations. In addition, GABA enhancer treatments, such as rac-hopantenic acid (pantogam activ) [102, 103] and adaptol [104], remarkably improved psychopathological, psychometric, and detailed somatic functions (e.g., cognitive functions, but also emotional state) with reduced adverse events (e.g., drowsiness and headaches) in patients with chronic cerebral ischemia. Therefore, developing new drugs of GABA enhancers with less adverse effects may be the next focus of clinical studies.…”
Section: The Role Of Gaba In Cerebral I/r Injury In Adultmentioning
confidence: 99%
“…However, adjustments of doses were complex and needed further investigations. In addition, GABA enhancer treatments, such as rac-hopantenic acid (pantogam activ) [102, 103] and adaptol [104], remarkably improved psychopathological, psychometric, and detailed somatic functions (e.g., cognitive functions, but also emotional state) with reduced adverse events (e.g., drowsiness and headaches) in patients with chronic cerebral ischemia. Therefore, developing new drugs of GABA enhancers with less adverse effects may be the next focus of clinical studies.…”
Section: The Role Of Gaba In Cerebral I/r Injury In Adultmentioning
confidence: 99%